title: KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition.
authors.forename: E
authors.initials: E
authors.lastname: Rouleau
authors.forename: F
authors.initials: F
authors.lastname: Spyratos
authors.forename: B
authors.initials: B
authors.lastname: Dieumegard
authors.forename: J M
authors.initials: JM
authors.lastname: Guinebretière
authors.forename: R
authors.initials: R
authors.lastname: Lidereau
authors.forename: I
authors.initials: I
authors.lastname: Bièche
mesh_terms: D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics* / Q000628:therapy; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D009154:Mutation / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics* / Q000378:metabolism
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins